Wednesday, October 7, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· December 16, 2025

TORM plc appoints Simon Mackenzie Smith as Chair of the Board

View original at finance.yahoo.com
TORM plc appoints Simon Mackenzie Smith as Chair of the Board INSIDE INFORMATION HELLERUP, Denmark, Dec. 16, 2025 /PRNewswire/ -- TORM plc (Nasdaq: TRMD or TRMD A) is pleased to announce that the Board of Directors has appointed Simon Mackenzie Smith as the new Chair of the Board, succeeding Chris Boehringer…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • I am honored to join TORM and look forward to further strengthening the position of the company. Together, we will focus on delivering long-term value for our customers and shareholders

    80% confidence

  • It has been a pleasure and an honor to serve as Chair of TORM. During this period, TORM has achieved significant long-term value creation for our shareholders, and I am confident that the competencies Simon Mackenzie Smith brings will support the continued development of TORM

    80% confidence

  • TORM has strengthened financial position and continued to develop the One TORM platform, which has been fundamental to continued market-leading performance

    80% confidence

  • The appointment follows a planned process and reflects the Board's strong focus on ensuring continuity and long-term value creation for TORM and shareholders

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com